Name | Validate

Amount in Lakhs

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr. No.	Details of the party (listed entity/subsidiary) entering into the transaction		Details of the counterparty									Income received/ paid to either party as a result of the transaction		Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.									
														In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Details of the loans, inter-corporate deposits, advances or investments					
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary	Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	Notes
1	RAD-SWIFT LABORATORIES LIMITED	AAACR4056G	ESSEX BIOSCIENCES LIMITED	AAACE3221P	Promoter	Investment		150000.00	As approved by Board/Shareholders			0.00	3985.06	3985.06									
2	RAD-SWIFT LABORATORIES LIMITED	AAACR4056G	ESSEX BIOSCIENCES LIMITED	AAACE3221P	Promoter	Purchase of goods or services		15000.00	As approved by Board/Shareholders			1707.83	3299.73	1429.65									
3	RAD-SWIFT LABORATORIES LIMITED	AAACR4056G	MOHSIJI GREEN ENVIRONMENT PRIVATE LIMITED	AACM3169J	Other RP	Advance		500.00	As approved by Board/Shareholders			0.00	22.00	22.00									
4	RAD-SWIFT LABORATORIES LIMITED	AAACR4056G	MOHSIJI GREEN ENVIRONMENT PRIVATE LIMITED	AACM3169J	Other RP	Investment		150000.00	As approved by Board/Shareholders			0.00	9.00	9.00									
5	RAD-SWIFT LABORATORIES LIMITED	AAACR4056G	RAD-SWIFT LABORATORIES INC, USA	Z2222WWRE	Wholly Owned Subsidiary	Sale of goods or services			Being a wholly owned subsidiary, there is no requirement			771.27	96.03	369.65									
6	RAD-SWIFT LABORATORIES LIMITED	AAACR4056G	RAD-SWIFT LABORATORIES INC, USA	Z2222WWRE	Wholly Owned Subsidiary	Investment			Being a wholly owned subsidiary, there is no requirement			0.00	544.10	544.10									
7	RAD-SWIFT LABORATORIES LIMITED	AAACR4056G	FORTUNE (INDIA) CONSTRUCTIONS LIMITED	AABCI3105M	Wholly Owned Subsidiary	Investment			Being a wholly owned subsidiary, there is no requirement			0.00	7338.43	7338.43									
8	RAD-SWIFT LABORATORIES LIMITED	AAACR4056G	NAVRATTAN MUNJAL	AAVPM2578A	Promoter	Remuneration			As approved by NRC/Board			131.28	72.91	72.78									
9	RAD-SWIFT LABORATORIES LIMITED	AAACR4056G	HIMANSHU JAIN	AGJPJ7267R	Promoter	Remuneration			As approved by NRC/Board			162.19	51.39	51.47									
10	RAD-SWIFT LABORATORIES LIMITED	AAACR4056G	RINKU MEHTA	AYPPM8077Q	Promoter	Remuneration			As approved by NRC/Board			177.01	56.95	85.82									
11	RAD-SWIFT LABORATORIES LIMITED	AAACR4056G	SAHIL MUNJAL	AITPM6982M	Promoter	Remuneration			As approved by NRC/Board			177.01	56.56	53.81									
12	RAD-SWIFT LABORATORIES LIMITED	AAACR4056G	GAGAN AGGARWAL	AAIPA6712G	CFO	Remuneration			As approved by NRC/Board			93.68	0.00	0.00									
13	RAD-SWIFT LABORATORIES LIMITED	AAACR4056G	PARDEEP VERMA	ABTPV7737B	Company Secretary	Remuneration			As approved by NRC/Board			25.64	0.00	0.00									
14	RAD-SWIFT LABORATORIES LIMITED	AAACR4056G	PARDEEP VERMA	ABTPV7737B	Company Secretary	Any other transaction	Loans & Advances		As approved by NRC/Board			0.00	9.15	9.15									
15	RAD-SWIFT LABORATORIES LIMITED	AAACR4056G	INDUS HEALTHCARE LLP	AAIF1977B	Joint Venture	Investment		1000.00	As approved by Board/Shareholders			0.00	250.00	250.00									
16	RAD-SWIFT LABORATORIES LIMITED	AAACR4056G	INDUS HEALTHCARE LLP	AAIF1977B	Joint Venture	Sale of goods or services		5000.00	As approved by Board/Shareholders			105.86	89.37	91.90									
17	RAD-SWIFT LABORATORIES LIMITED	AAACR4056G	MAV REMEDIES PRIVATE LIMITED	AAPCM9536C	Subsidiary	Investment		50.00	As approved by Board/Shareholders			0.00	23.25	23.25									
18	RAD-SWIFT LABORATORIES LIMITED	AAACR4056G	ESSEX BIOSCIENCES LIMITED	AAACE3221P	Promoter	Sale of goods or services		15000.00	As approved by Board/Shareholders			0.13	0.77	0.06									
19	RAD-SWIFT LABORATORIES LIMITED	AAACR4056G	MAV REMEDIES PRIVATE LIMITED	AAPCM9536C	Subsidiary	Sale of goods or services		5000.00	as approved by audit committee			0.00	8.16	8.16									
20	RAD-SWIFT LABORATORIES LIMITED	AAACR4056G	ELAD VITAL DRUG STORE LLC	Z2222WWRE	Other RP	Sale of goods or services		5000.00	as approved by audit committee			533.16	967.07	1298.59									
21	RAD-SWIFT LABORATORIES LIMITED	AAACR4056G	CHEMIST TIME CREATES	Z2222WWRE	Other RP	Sale of goods or services		5000.00	as approved by audit committee			26.92	551.32	551.34									
22	RAD-SWIFT LABORATORIES LIMITED	AAACR4056G	GOPAL MUNJAL	AAVPM2320M	Promoter	Any other transaction	Advance against salary		as per HR's policy			0.00	305.79	305.79									
23	RAD-SWIFT LABORATORIES LIMITED	AAACR4056G	V.K. MEHTA	AAVPM2007J	Promoter	Any other transaction	Advance against salary		as per HR's policy			0.00	363.19	363.19									
24	RAD-SWIFT LABORATORIES LIMITED	AAACR4056G	V.K. MEHTA	AAVPM2579Q	Promoter	Any other transaction	Advance against salary		as per HR's policy			0.00	356.18	356.18									
25	RAD-SWIFT LABORATORIES LIMITED	AAACR4056G	MUNJAL JAINISTATED PVT LTD	AADCM2830D	Other RP	Loan		1000.00	1000			26.60	666.18	637.78									
26	RAD-SWIFT LABORATORIES LIMITED	AAACR4056G	ISLL MIDDLE EAST L.L.C *2	Z2222WWRE	Wholly Owned Subsidiary	Investment			Being a wholly owned subsidiary, there is no requirement			686.75	2736.17	3210.92									
27	FORTUNE (INDIA) CONSTRUCTIONS LIMITED	AABCI3105M	ESSEX BIOSCIENCES LIMITED	AAACE3221P	Other RP	Investment			as approved by audit committee			0.00	3556.93	3556.93									The outstanding balance pertains to the period prior to Fortune (India) Constructions Limited becoming a subsidiary of the Company. Fortune (India) Constructions Limited became a subsidiary during FY 2021-22, accordingly, the balance relates to transactions existing before the acquisition.
28	FORTUNE (INDIA) CONSTRUCTIONS LIMITED	AABCI3105M	ESSEX BIOSCIENCES LIMITED	AAACE3221P	Other RP	Investment			as approved by audit committee			0.00	380.55	380.55									The outstanding balance pertains to the period prior to Fortune (India) Constructions Limited becoming a subsidiary of the Company. Fortune (India) Constructions Limited became a subsidiary during FY 2021-22, accordingly, the balance relates to transactions existing before the acquisition.
29	RAD-SWIFT LABORATORIES LIMITED	AAACR4056G	Gopal Munjal	AAVPM2320M	Promoter	Remuneration		2600.00	As approved by Shareholders			89.94	0.00	0.00									
30	RAD-SWIFT LABORATORIES LIMITED	AAACR4056G	V.K. Mehta	AAVPM2007J	Promoter	Remuneration		2600.00	As approved by Shareholders			89.94	0.00	0.00									
31	RAD-SWIFT LABORATORIES LIMITED	AAACR4056G	V.K. Mehta	AAVPM2579Q	Promoter	Remuneration		2600.00	As approved by Shareholders			89.93	0.00	0.00									
32	RAD-SWIFT LABORATORIES LIMITED	AAACR4056G	Capital Brokers LLP	AAVCP3819C	Joint venture	Investment		200.00	As approved by Board/Audit Committee			0.00	0.25	0.25									
33	RAD-SWIFT LABORATORIES LIMITED	AAACR4056G	MAV REMEDIES PRIVATE LIMITED	AAPCM9536C	Subsidiary	Advance		5000.00	As approved by Board/Audit Committee			6.75	0.00	6.75									
Total value of transaction during the reporting period												4798.33											

Notes
1. The details in this format are required to be provided for all transactions undertaken during the reporting period. However, opening and closing balances, including commitments, to be disclosed for existing related party transactions even if there is no new related party transaction during the reporting period.
2. Where a transaction is undertaken between members of the consolidated entity (between the listed entity and its subsidiary or between subsidiaries), it may be reported once.
3. Where the details of the counterparty are not available with the listed entity, it may disclose the details available with it. For example, in case of investments made or given by the listed banks.
4. For companies with financial year ending March 31, this information has to be provided for six months ended September 30 and six months ended March 31.
Companies with financial years ending in other months, the six months period shall apply accordingly.
5. Each type of related party transaction (for e.g. sale of goods/services, purchase of goods/services or whether it involves a loan, inter-corporate deposit, advance or investment) with a single party shall be disclosed separately and there should be no clubbing or netting of transactions of same type.
6. Transactions entered with the same counterparty of the same type may be aggregated for the reporting period. For instance, sale transactions with the same party may be aggregated for the reporting period and purchase transactions may also be disclosed in a similar manner. There should be no netting off for sale and purchase transactions. Similarly, loans advanced to and received from the same counterparty should be disclosed separately, without any netting off.
8. In case of a multi-year related party transaction:
a. The aggregate value of such related party transaction as approved by the audit committee shall be disclosed in the column "Value of the related party transaction as approved by the audit committee"
b. The value of the related party transaction ratified by the audit committee shall be disclosed in the column "Value of the related party transaction ratified by the audit committee"
c. The value of the related party transaction undertaken in the reporting period shall be reported in the column "Value of related party transaction during the reporting period"
7. "Cost" refers to the cost of borrowed funds for the listed entity. 8. Transactions such as acceptance of fixed deposits by banks/NBFCs, undertaken with related parties, on the terms uniformly applicable (offered to all shareholders/ public shall also be reported.